1. Background {#sec1-antibiotics-08-00124}
=============

Several immunosuppressive agents are associated with many undesired side-effects involving oral tissue alterations \[[@B1-antibiotics-08-00124],[@B2-antibiotics-08-00124]\]. Drug-induced gingival overgrowth (DIGO) is the most commonly encountered side effect of a plethora of medications \[[@B3-antibiotics-08-00124]\], showing a high prevalence in response to calcineurin inhibitors such as cyclosporine-A \[[@B4-antibiotics-08-00124],[@B5-antibiotics-08-00124],[@B6-antibiotics-08-00124]\]. The severity of gingival hyperplasia clinical manifestation is also related to calcium channel blocker agent association, frequently provided in addition to pharmacological therapy for transplant recipients \[[@B7-antibiotics-08-00124],[@B8-antibiotics-08-00124]\]. Specifically, the nifedipine-induced enlargements have a higher prevalence rate compared to the amlodipine-induced enlargements, that is, 47.8% and 3.3% respectively \[[@B9-antibiotics-08-00124],[@B10-antibiotics-08-00124]\]. According to epidemiological available data, although reports vary widely, the overall estimated prevalence is about 30% with a range from 6% to 81% \[[@B2-antibiotics-08-00124]\], but the occurrence has not been systematically compiled. A higher prevalence (from 48% to 60%) has been reported in the case of therapy combining cyclosporine and nifedipine or amlodipine therapy \[[@B11-antibiotics-08-00124],[@B12-antibiotics-08-00124]\]. Males are more commonly affected than females by a ratio of 3:1 \[[@B13-antibiotics-08-00124]\]. The underlying pathophysiology of gingival enlargement is multifactorial and may vary considerably between individuals \[[@B14-antibiotics-08-00124],[@B15-antibiotics-08-00124]\]. One factor believed to play a critical role in the pathogenesis of the lesion is bacterial plaque accumulation and pre-existing periodontal inflammatory status \[[@B16-antibiotics-08-00124],[@B17-antibiotics-08-00124]\]. Furthermore, the exposure to bacterial plaque and poor oral hygiene are well-established amplifier risk factors for severity degree of DIGO. In addition, there is some evidence concerning the contribution of genetic factors to the risk of the onset of GO \[[@B18-antibiotics-08-00124]\]. However, the specific mechanism responsible for the variability is still unclear.

Clinically, hyperplasia first frequently appears within 1--3 months following initiation of immunosuppressant therapy, involving primarily the interproximal gingival area. Gradually, fibrotic enlargement evolves, extending up to cover dental crowns \[[@B19-antibiotics-08-00124],[@B20-antibiotics-08-00124]\]. Histologically, it is described as connective tissue disorder, characterized by excessive interstitial collagen deposition, due to metabolic alteration of gingival fibroblasts, increased inflammatory response and altered vascularization. It's widely recognized that connective tissue fibroblasts demonstrate heterogeneity in response to various stimuli \[[@B21-antibiotics-08-00124],[@B22-antibiotics-08-00124]\]. In addition to the commonly seen histopathological patterns of lesions, consisting of an accumulation of connective tissue matrix within the gingival propria, distinct and phenotypically stable subpopulations of fibroblasts existing within gingiva and other connective tissues characterize the damaged tissue \[[@B23-antibiotics-08-00124]\]. Altered production of collagen and of the other components of the extracellular matrix, the imbalance between synthesis and degradation of the ECM proteins and an altered proliferation rate typify these subpopulations functionally \[[@B23-antibiotics-08-00124]\]. In addition, environmental factors are involved in disease predisposition \[[@B24-antibiotics-08-00124],[@B25-antibiotics-08-00124],[@B26-antibiotics-08-00124]\]. Histological studies suggest that susceptibility is genetically determined in the cyclosporine-sensitive subpopulation of gingival fibroblasts \[[@B27-antibiotics-08-00124]\]. Additional evidence supporting fibroblast heterogeneity has been provided by laboratory animal studies, showing an increase of gingival fibroblast growth and synthetic activity by cyclosporine-A \[[@B28-antibiotics-08-00124]\]. Cell-to-cell variability in the population growth rate has since been observed actively \[[@B29-antibiotics-08-00124],[@B30-antibiotics-08-00124],[@B31-antibiotics-08-00124],[@B32-antibiotics-08-00124]\]. Interestingly, in order to assess fibroblast heterogeneity in collagenolytic response to cyclosporine collagenases activity, and tissue inhibitor of metalloproteinase (TIMP) in 14 different strains of connective tissue fibroblasts obtained from healthy individuals without periodontal inflammation were studied in vitro \[[@B33-antibiotics-08-00124],[@B34-antibiotics-08-00124]\]. The results confirmed the influence of interindividual susceptibility to CsA-induced gingival overgrowth. Some studies reported a wide inter-individual variability \[[@B35-antibiotics-08-00124],[@B36-antibiotics-08-00124]\] depending primarily on hereditary genetic variation \[[@B37-antibiotics-08-00124]\] in drug metabolizing enzymes as a consequence of cytochrome P450 genetic polymorphisms \[[@B21-antibiotics-08-00124],[@B37-antibiotics-08-00124],[@B38-antibiotics-08-00124]\], a major source of variability of response to drug pharmacokinetics. Specifically, cyclosporine is metabolized by CYP3A4 cytochrome P450 isoenzyme \[[@B39-antibiotics-08-00124],[@B40-antibiotics-08-00124],[@B41-antibiotics-08-00124]\]. However, cytochrome P450 is also altered in common clinical conditions (e.g., diabetes mellitus) usually associated with periodontal infections \[[@B42-antibiotics-08-00124],[@B43-antibiotics-08-00124],[@B44-antibiotics-08-00124]\], sometimes evolving in harmful conditions in immune suppressed patients \[[@B45-antibiotics-08-00124],[@B46-antibiotics-08-00124],[@B47-antibiotics-08-00124]\].

The management options for gingival DIGO includes a customized oral hygiene protocol, known as dental biofilm detection topographic technique (D-Biotech) \[[@B48-antibiotics-08-00124]\], which facilitates ergonomic and non-invasive treatment, and non-surgical periodontal therapy to reduce the inflammatory component, and a consequent surgical approach is needed for reduction of gingival mass. \[[@B48-antibiotics-08-00124]\].

2. Materials and Methods {#sec2-antibiotics-08-00124}
========================

Our study analyzed data from 72 kidney transplant patients, from the Complex Nephrology Operative Unit, S.S. Annunziata of Chieti. Written informed consent was obtained from all patients in a pre-operative clinic assessment. Patients underwent a comprehensive periodontal examination including plaque index (PI), gingival index (GI), pocket depth (PD), clinical attack loss (CAL). The measurements were determined at six sites per tooth (mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual, and distolingual), excluding third molars. The Miller and Damm (1992) modified index for enhanced assessment of gingival overgrowth was used. The vertical gingival overgrowth index was described as: (a) Grade 0: normal gingival, no alteration; (b) Grade 1: minimal overgrowth, ≤2 mm, gingiva covering the cervical third or less of the anatomic crown; (c) Grade 2: moderate overgrowth: 2 to 4 mm, gingival covering the middle third of the anatomic crown; (d) Grade 3: severe overgrowth: ≥4 mm, nodular growth, gingival covering more than two thirds of the dental crown. The horizontal gingival overgrowth index is described as: (a) Grade 0: \<1 mm; (b) Grade 1: 1 to 2 mm; (c) Grade 2: \>2 mm. The possible onset of gingival overgrowth was also recorded, with the related degree of severity (from 0 to 3). The clinical examination was performed by a single calibrated examiner using a manual probe (UNC-15, Hu-Friedy Manufacturing Company, Inc., Chicago, IL, USA). Periodontal treatment was performed using ultrasonic and manual instruments. Clinical evaluations were assessed at baseline and at 3 months, 6 months and 9 months.

3. Statistical Analysis {#sec3-antibiotics-08-00124}
=======================

All data obtained during the study were recorded in individual charts and then transferred to the database in Excel Office 2013. The data were processed and analyzed using Statistical Package for the Social Sciences (IBM SPSS 19.0, SPSS Inc., Chicago, IL, USA) version 19. Descriptive statistical analysis included the arithmetic mean and standard deviation. Drug-induced gingival overgrowth prevalence and incidence were calculated with the direct method. The Mann-Whitney test was used to compare medians between treatments. Non-parametric test (Kruskall-Wallis H test) was used to calculate the difference in medians between two independent samples (immunosuppressive treatment). Pearson's correlation was used to assess the relationship between prevalence of DIGO and periodontal clinical parameters at different times: T0 (baseline), T1 (three months), T2 (six months), T3 (nine months).

The first part of the study saw a descriptive analysis of the population in question ([Figure 1](#antibiotics-08-00124-f001){ref-type="fig"}, [Figure 2](#antibiotics-08-00124-f002){ref-type="fig"} and [Figure 3](#antibiotics-08-00124-f003){ref-type="fig"}).

4. Results {#sec4-antibiotics-08-00124}
==========

About 45.84% of the participants were treated with cyclosporine and 54.16% reporting treatment with tacrolimus (Graph 1). Of the examined population, 22.23% received immunosuppressant therapy without additional calcium-channel blockers, 62.5% received immunosuppressant drug administration in addition to the nifedipine, and 15.27% with the amlodipine (Graph 2). The clinical parameter GO showed no differences between cyclosporine and tacrolimus groups at baseline, 3, 6, and months; PD and CAL also showed no significant differences between groups at 4 times; and the tacrolimus group showed significantly greater GI and PI reduction at 3, 6 and 9 months than the cyclosporine group. Significant correlation between PI and GI was observed (*P* \< 0.05) ([Table 1](#antibiotics-08-00124-t001){ref-type="table"}). The difference in the medians of GI and PI of the two groups at 6 and 9 months is less in the tacrolimus group than in the cyclosporine group ([Figure 4](#antibiotics-08-00124-f004){ref-type="fig"}, [Figure 5](#antibiotics-08-00124-f005){ref-type="fig"}, [Figure 6](#antibiotics-08-00124-f006){ref-type="fig"} and [Figure 7](#antibiotics-08-00124-f007){ref-type="fig"}). When conducting an intergroup comparison, no difference was found in the medians for immunosuppressant treatments in addition to calcium-antagonists and periodontal parameters at, 3, 6 and 9 months follow-up ([Figure 8](#antibiotics-08-00124-f008){ref-type="fig"}, [Figure 9](#antibiotics-08-00124-f009){ref-type="fig"}, [Figure 10](#antibiotics-08-00124-f010){ref-type="fig"} and [Figure 11](#antibiotics-08-00124-f011){ref-type="fig"}). The decrease in the GO parameter was more in the tacrolimus plus calcium-channel blocker group compared with the other treatment groups, but the difference was not statistically significant (*P* \> 0.05) ([Table 2](#antibiotics-08-00124-t002){ref-type="table"} and [Table 3](#antibiotics-08-00124-t003){ref-type="table"}). Results of a correlation analysis showed a positive correlation of GO with all variables (*P* \< 0.05), but with exceptions as follows: at 3 months, except PD; at 6 months except, PI and GI; at 9 months except PI and GI ([Table 4](#antibiotics-08-00124-t004){ref-type="table"}, [Table 5](#antibiotics-08-00124-t005){ref-type="table"}, [Table 6](#antibiotics-08-00124-t006){ref-type="table"} and [Table 7](#antibiotics-08-00124-t007){ref-type="table"}).

5. Discussion {#sec5-antibiotics-08-00124}
=============

The current state of knowledge of the prevalence of drug-induced gingival overgrowth is derived from retrospective studies and clinical trials with high heterogeneity in method. The estimates of cumulative prevalence of DIGO in transplant patients treated by immunosuppressant ranges from 6% to 81% \[[@B3-antibiotics-08-00124]\]. It has been reported that gingival lesion occurs mainly in patients with poor oral health and compromised periodontal status \[[@B31-antibiotics-08-00124]\]. Therefore, in the present study, gingival overgrowth was strictly analyzed previously as a lesion linked to pre-existent periodontal inflammation. Then, the effect of varying immunosuppressants was evaluated in combination with calcium-channel blockers (CCBs), demonstrating no statistical differences in degree of gingival enlargement between groups. Our findings are consistent with previous studies which have also confirmed that patients in treatment with cyclosporine exhibit significantly greater risk of gingival overgrowth onset compared with patients in treatment with tacrolimus \[[@B22-antibiotics-08-00124],[@B23-antibiotics-08-00124],[@B24-antibiotics-08-00124]\].

The specific mechanism of cyclosporine-induced gingival overgrowth is uncertain. One explanation may be that the accumulation of gingival fibroblasts may result from the inhibition of apoptosis \[[@B49-antibiotics-08-00124]\], because of the direct effect of cyclosporine metabolites on gingival fibroblasts, protein synthesis and collagen production \[[@B50-antibiotics-08-00124]\]. Further, in vitro studies were conducted to investigate the pro-proliferative, antiproliferative \[[@B51-antibiotics-08-00124]\], pro-apoptotic, antiapoptotic \[[@B52-antibiotics-08-00124]\], or no effect of cyclosporine on gingival keratinocytes, reporting an increased release of keratinocyte growth factor in epithelial cells observed in CsA-induced gingival hyperplasia, but the findings were inconclusive.

The results of the present study are also in accordance with previous studies showing that the degree of gingival overgrowth may favorably improve after the periodontal inflammation clinical parameters decrease. Indeed, it has been amply demonstrated that the upregulation of salivary concentrations of proinflammatory cytokines such as interleukin (IL) 1α, IL-8, and IL-6 is implicated in the pathogenesis of cyclosporine-induced gingival overgrowth. So, maintaining periodontal health may markedly reduce the severity of CsA-induced gingival hyperplasia \[[@B52-antibiotics-08-00124],[@B53-antibiotics-08-00124]\].

6. Conclusions {#sec6-antibiotics-08-00124}
==============

Drug-induced gingival overgrowth represents the most frequent adverse reaction in patients taking immunosuppressant drugs, with lower incidence in patients taking tacrolimus. In addition, many studies have reported a higher prevalence of gingival lesion in patients also receiving calcium channel blockers. In our study, a significant positive correlation was found between prevalence of gingival overgrowth and cyclosporine. The slightly lesser GO degree in the calcium-channel blocker group compared to the cyclosporine group may be attributed to the low dosage of drugs.

Although the disorder recognizes a multifactorial genesis, periodontal status is critical in determining the severity and recurrence of the lesion. In conclusion, the results of the present study showed a significant improvement in clinical parameters such as GI, PI and GO between groups, confirming the key role of periodontal inflammation in the pathogenesis of gingival enlargement.
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antibiotics-08-00124-t001_Table 1

###### 

Kruskall-Wallis (non-parametric) test for median difference between two independent samples (immunosuppressive treatment).

  Statistic Tests ^a^                               
  --------------------- --------- --------- ------- -------
  PI T0                 269,500   675,500   −994    0.320
  PI T1                 269,500   675,500   −996    0.319
  PI T2                 165,500   571,500   −2974   0.003
  PI T3                 189,000   595,000   −2528   0.011
  GI T0                 230,000   636,000   −1742   0.081
  GI T1                 235,000   641,000   −1649   0.099
  GIT2                  184,500   590,500   −2616   0.009
  GI T3                 133,000   539,000   −3597   0.000
  GO T0                 250,000   656,000   −1744   0.081
  GO T1                 308,000   714,000   −1103   0.270
  GO T2                 308,000   714,000   −1103   0.270
  GO T3                 308,000   714,000   −1103   0.270
  PD T0                 279,500   685,500   −805    0.421
  PD T1                 278,500   684,500   −824    0.410
  PD T2                 283,000   689,000   −739    0.460
  PD T3                 299,500   705,500   −428    0.669
  CAL T0                278,500   684,500   −824    0.410
  CAL T1                272,000   678,000   −947    0.343
  CAL T2                253,000   659,000   −1307   0.191
  CAL T3                259,000   665,000   −1194   0.232

^a.^ Grouping variable: Immunosuppressants.

antibiotics-08-00124-t002_Table 2

###### 

Kruskall-Wallis H test for the difference between GO means.

  Statistic Tests ^a,b^                           
  ----------------------- ------- ------- ------- -------
  H of Kruskal-Wallis     6434    2923    2923    2923
  gl                      5       5       5       5
  Asymptotic sign.        0.266   0.712   0.712   0.712

^a.^ Kruskal Wallis's Test; ^b.^ Grouping variable: Immunosuppressants + calcium-channel blockers.

antibiotics-08-00124-t003_Table 3

###### 

Correlations between GO and periodontal indices.

  Statistics Tests ^a,b^                
  ------------------------ -------- --- -------
  PI T0                    7880     5   0.163
  PI T1                    5710     5   0.335
  PI T2                    11,280   5   0.046
  PI T3                    6776     5   0.238
  GI T0                    7979     5   0.157
  GI T1                    6311     5   0.277
  GI T2                    9126     5   0.104
  GI T3                    13,809   5   0.017
  PD T0                    7601     5   0.180
  PD T1                    6852     5   0.232
  PD T2                    7661     5   0.176
  PD T3                    7136     5   0.211
  CAL T0                   6757     5   0.239
  CAL T1                   3897     5   0.564
  CAL T2                   5310     5   0.379
  CAL T3                   6844     5   0.232

^a.^ Kruskal Wallis Test; ^b.^ Grouping variable: Immunosuppressants + calcium-channel blockers.

antibiotics-08-00124-t004_Table 4

###### 

Correlation between GO degree and periodontal indices at baseline.

  Correlations                                     
  ------------------------ ----------------------- -------
  GO T0                    Pearson's correlation   1
  N                        51                      
  PI T0                    Pearson's correlation   0.512
  Sign. (with two tails)   0.000                   
  N                        51                      
  GI T0                    Pearson's correlation   0.621
  Sign. (with two tails)   0.000                   
  N                        51                      
  PD T0                    Pearson's correlation   0.351
  Sign. (with two tails)   0.012                   
  N                        51                      
  CAL T0                   Pearson's correlation   0.358
  Sign. (with two tails)   0.010                   
  N                        51                      

antibiotics-08-00124-t005_Table 5

###### 

Correlation between GO degree and periodontal indices at T1.

  Correlations                                     
  ------------------------ ----------------------- -------
  GO T1                    Pearson's correlation   1
  N                        51                      
  PI T1                    Pearson's correlation   0.625
  Sign. (with two tails)   0.000                   
  N                        51                      
  GI T1                    Pearson's correlation   0.455
  Sign. (with two tails)   0.001                   
  N                        51                      
  PD T1                    Pearson's correlation   0.243
  Sign. (with two tails)   0.085                   
  N                        51                      
  CAL T1                   Pearson's correlation   0.333
  Sign. (with two tails)   0.017                   
  N                        51                      

antibiotics-08-00124-t006_Table 6

###### 

Correlation between GO degree and periodontal indices at T2.

  Correlations                                     
  ------------------------ ----------------------- -------
  GO T2                    Pearson's correlation   1
  N                        51                      
  PI T2                    Pearson's correlation   0.183
  Sign. (with two tails)   0.200                   
  N                        51                      
  GI T2                    Pearson's correlation   0.163
  Sign. (with two tails)   0.253                   
  N                        51                      
  PD T2                    Pearson's correlation   0.303
  Sign. (with two tails)   0.031                   
  N                        51                      
  CAL T2                   Pearson's correlation   0.383
  Sign. (with two tails)   0.006                   
  N                        51                      

antibiotics-08-00124-t007_Table 7

###### 

Correlation between GO degree and periodontal indices at T3.

  Correlations                                     
  ------------------------ ----------------------- -------
  GO T3                    Pearson's correlation   1
  N                        51                      
  PI T3                    Pearson's correlation   0.183
  Sign. (with two tails)   0.200                   
  N                        51                      
  GI T3                    Pearson's correlation   0.163
  Sign. (with two tails)   0.253                   
  N                        51                      
  PD T3                    Pearson's correlation   0.303
  Sign. (with two tails)   0.031                   
  N                        51                      
  CAL T3                   Pearson's correlation   0.383
  Sign. (with two tails)   0.006                   
  N                        51                      
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